Vir Biotechnology, Inc. — Director's Dealing 2023

Mar 29, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2023-03-27

Reporting Person: Lee Sung (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-27	Common Stock	A	66500	$0.00	Acquired	66500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-27	Stock Option (Right to Buy)	$23.01	A	133000	Acquired	2033-03-26	Common Stock (133000)	Direct

Footnotes

F1: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.

F2: 25% of the shares subject to the stock option vest and become exercisable on March 27, 2024, and the remainder vest in 36 equal monthly installments thereafter.